Ignasi Charles-Pau
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis.
Journal: The Journal of dermatological treatment
Published: July 25, 2025
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials.
Journal: The Journal of dermatological treatment
Published: April 28, 2024
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).
Journal: Dermatology and therapy
Published: October 17, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 24, 2021
Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020.
Journal: Expert review of clinical immunology
Published: April 26, 2021
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 17, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Journal: The British journal of dermatology
Published: February 04, 2021
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Journal: The British journal of dermatology
Published: June 17, 2019
Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 15, 2019
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis.
Journal: Experimental dermatology
Published: March 22, 2018
Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
Journal: Archives of dermatological research
Published: August 10, 2017
First-line treatment in lymphomatoid papulosis: a retrospective multicentre study.
Journal: Clinical and experimental dermatology
Published: December 29, 2016
Last Updated: 09/26/2026